AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03578172
Drug: hormone replacement therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.
Trial: NCT00212030
Drug: nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
Trial: NCT00530257
Drug: OROS-methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 mg to 54 mg once a day for 1 week
Trial: NCT04446377
Drug: Apilimod Dimesylate Capsule
RxNorm normalized name: mesylate
DrugBank: Apilimod (DB05611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
Trial: NCT01733407
Drug: L-serine
RxNorm normalized name: L-Serine
DrugBank: Serine (DB00133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
Trial: NCT03075163
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
Trial: NCT02496832
Drug: 18F-Fluoroazomycin arabinoside
RxNorm normalized name: 18F-Fluoroazomycin arabinoside
DrugBank: Fluoroazomycin arabinoside F-18 (DB15134)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03629717
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
Trial: NCT03629717
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU daily
Trial: NCT02198248
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
Trial: NCT01487369
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
Trial: NCT03146962
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
Trial: NCT03435107
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study treatment consists of durvalumab 1500 mg Q4W for patients \> 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study.
Trial: NCT00165308
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally, daily for one year.
Trial: NCT01257243
Drug: Syrup of oxomemazine, guaifenesin and potassium iodate
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5ml each 4 hours
Trial: NCT01257243
Drug: Syrup of guaifenesin
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5ml each 4 hours
Trial: NCT04501705
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator.
Trial: NCT02904265
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02904265
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03083080
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL 0.5% ropivacaine is used to achieve VATS block
Trial: NCT02150993
Drug: Tenofovir + Emtricitabine or Lamivudine + Zidovudine
RxNorm normalized name: lamivudine / zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
Trial: NCT02150993
Drug: Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
Trial: NCT02150993
Drug: Tenofovir + Emtricitabine or Lamivudine + Raltegravir
RxNorm normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
Trial: NCT05008250
Drug: metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
Trial: NCT02394847
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01526616
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850 mg twice a day for six months
Trial: NCT00285597
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04347239
Drug: Leronlimab (700mg)
RxNorm normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Trial: NCT01166724
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tacrolimus to Sirolimus
Trial: NCT01166724
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage per trough level
Trial: NCT00383149
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
Trial: NCT00383149
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
Trial: NCT02457910
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02457910
Drug: Taselisib
RxNorm normalized name: Taselisib
DrugBank: Taselisib (DB12108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03434054
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blood pressure medication
Trial: NCT00450333
Drug: Dynepo (Epoetin delta)
DrugBank: Epoetin delta (DB11624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, BIW for 24 weeks
Trial: NCT00450333
Drug: Dynepo
DrugBank: Epoetin delta (DB11624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, QW for 24 weeks
Trial: NCT00450333
Drug: Dynepo
DrugBank: Epoetin delta (DB11624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, Q2W for 24 weeks
Trial: NCT01471106
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day.
Trial: NCT04319900
Drug: favipiravir tablets+chloroquine phosphatetablets tablets
RxNorm normalized name: chloroquine Oral Tablet
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.
Trial: NCT00388271
Drug: Alfuzosin (Xatral)
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard treatment plus alfuzosin
Trial: NCT03107754
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
Trial: NCT01673919
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg iv every 4 weeks, 104 weeks
Trial: NCT03107754
Drug: Lidocaine-Sodium Bicarbonate
RxNorm normalized name: lidocaine-sodium bicarbonate
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
Trial: NCT02060604
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 monthly ranibizumab, then as needed
Trial: NCT04164719
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
Trial: NCT01326689
Drug: KW-2246
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication at an optimal dose, which is determined by dose titration
Trial: NCT03220633
Drug: ATB-346
RxNorm normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01660373
Drug: Tirofiban
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4ug/kg/min for 30min followed by 0.1ug/kg/min
Trial: NCT01660373
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose(180mg) followed by maintenance dose(90mg bid)
Trial: NCT00003053
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003053
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00124657
Drug: Erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
Trial: NCT01903720
Drug: dexamethasone implant
RxNorm normalized name: dexamethasone Drug Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
Trial: NCT03374956
Drug: Phentermine-Topiramate
RxNorm normalized name: phentermine-topiramate
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended Release at dose of 7.5/46 mg oral daily
Trial: NCT03374956
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dose of 3 mg subcutaneous daily
Trial: NCT03374956
Drug: Naltrexone/bupropion
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
Trial: NCT03374956
Drug: Phentermine
RxNorm normalized name: Phentermine
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-37.5 mg oral daily
Trial: NCT04319900
Drug: Favipiravir tablets
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Trial: NCT02383810
Drug: Elsiglutide
RxNorm normalized name: Elsiglutide
DrugBank: Elsiglutide (DB06336)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00398879
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine 50 mg/d qd
Trial: NCT01464606
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
Trial: NCT01131923
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine Tablets, 10 mg
Trial: NCT03249298
Drug: Sterofundin (Bolus of crystalloids)
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus of 250 ml crystaloids infused regarding the measures
Trial: NCT03249298
Drug: Voluven (Bolus of colloids)
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of 250 ml colloids infused regarding the measures
Trial: NCT00955526
Drug: Istradefylline
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
Trial: NCT00955526
Drug: Istradefylline
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
Trial: NCT00071279
Drug: SR34006 (idraparinux sodium) Injection
RxNorm normalized name: Idraparinux
DrugBank: Idraparinux (DB06406)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01464606
Drug: Dactinomycin
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
Trial: NCT01464606
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
Trial: NCT04567433
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch compared to 0.9% saline
Trial: NCT01991457
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00541034
Drug: pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00035620
Drug: pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pegfilgrastim
Trial: NCT00035620
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: filgrastim
Trial: NCT00363038
Drug: Petrolatum United States Pharmacopeia (USP)
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formation applied to bruise twice daily for 2 weeks.
Trial: NCT03444519
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
Trial: NCT00363038
Drug: Vitamin K and retinol ointment
RxNorm normalized name: retinol (vit A)
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formation applied to bruise twice daily for 2 weeks.
Trial: NCT00363038
Drug: Arnica ointment
RxNorm normalized name: Arnica Ointment
DrugBank: Arnica montana (DB14297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formation applied to bruise twice daily for 2 weeks.
Trial: NCT00553150
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00553150
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02606994
Drug: Crest Toothpaste
RxNorm normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush with Crest Toothpaste three times per day during the study
Trial: NCT02606994
Drug: Magic Mouth Rinse
RxNorm normalized name: Boo-Boo Magic
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
Trial: NCT01980875
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg tablet administered orally twice daily
Trial: NCT01980875
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
Trial: NCT01980875
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
Trial: NCT00665847
Drug: Etravirine (TMC125)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
Trial: NCT04229615
Drug: Fluzoparib; Apatinib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
Trial: NCT04229615
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib Orally twice daily
Trial: NCT04234321
Drug: basic fibroblast growth factor
RxNorm normalized name: Basic Fibroblast Growth Factor
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
Trial: NCT00437554
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00975481
Drug: dimebon
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet; 20 mg dimebon, single dose